Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856471 | 1.00 | MAPK14 (0.42) | MAPK14FGFR1MAPK1ADORA2AADORA1 | |
| SCHEMBL4852870 | 0.91 | FGFR1 (0.38) | MAPK14FGFR1MAPK1ADORA2AADORA1 | |
| SCHEMBL4852879 | 0.91 | FGFR1 (0.38) | MAPK14FGFR1MAPK1ADORA2AADORA1 | |
| SCHEMBL4858023 | 0.88 | MAPK14 (0.47) | MAPK14FGFR1MAPK1FGFR2MAPK13 | |
| SCHEMBL4848763 | 0.87 | WEE1 (0.40) | MAPK14FGFR1FGFR2WEE1MAPK13 | |
| SCHEMBL4848856 | 0.86 | MAPK14 (0.41) | MAPK14FGFR1WEE1MAPK13MAPK12 | |
| SCHEMBL4848848 | 0.86 | MAPK14 (0.41) | MAPK14FGFR1WEE1MAPK13MAPK12 | |
| SCHEMBL4857416 | 0.79 | MAPK14 (0.37) | MAPK14FGFR1MAPK1MAPK13MAPK12 | |
| SCHEMBL4857398 | 0.79 | MAPK14 (0.37) | MAPK14FGFR1MAPK1MAPK13MAPK12 | |
| SCHEMBL4889580 | 0.79 | WEE1 (0.39) | MAPK14FGFR1FGFR2WEE1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | claimed |
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-7319102-B1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | DPYD, IL1B, IL6 | MAPK14 2806/4885FGFR1 573/4885MAPK1 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.